Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply

被引:0
作者
Guttman-Yassky, Emma [1 ,2 ]
Simpson, Eric L. [3 ]
Reich, Kristian [4 ]
Kabashima, Kenji [5 ]
Igawa, Ken [6 ]
Suzuki, Tetsuya [7 ]
Mano, Hirotaka [7 ]
Matsui, Takeshi [7 ]
Esfandiari, Ehsanollah [8 ]
Furue, Masutaka [9 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Allergy & Immunol, New York, NY 10029 USA
[3] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA
[4] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
[5] Kyoto Univ, Dept Dermatol, Kyoto, Japan
[6] Dokkyo Med Univ, Dept Dermatol, Tochigi, Japan
[7] Kyowa Kirin, Tokyo, Japan
[8] Kyowa Kirin Int, London, England
[9] Kyushu Univ, Dept Dermatol, Fukuoka, Japan
关键词
D O I
10.1016/S0140-6736(23)01618-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1834 / 1834
页数:1
相关论文
共 1 条
[1]   An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study [J].
Guttman-Yassky, Emma ;
Simpson, Eric L. ;
Reich, Kristian ;
Kabashima, Kenji ;
Igawa, Ken ;
Suzuki, Tetsuya ;
Mano, Hirotaka ;
Matsui, Takeshi ;
Esfandiari, Ehsanollah ;
Furue, Masutaka .
LANCET, 2023, 401 (10372) :204-214